Renshaw Healthcare Conference

RNS Number : 6703H

Oxford Biomedica PLC

07 November 2008

 



For Immediate Release	7 NOVEMBER 2008

OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW 10TH ANNUAL HEALTHCARE CONFERENCE

Oxford, UK - 7 November 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Nick Woolf, Oxford BioMedica's Chief Business Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York City on Tuesday, 11 November 2008 at 9.55pm GMT (4.55pm ET).

The presentation will be webcast live and may be accessed under the investors section of the Company's website, www.oxfordbiomedica.co.uk. The presentation will also be available for replay.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Chief Executive Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Katja Stout/ Holly Griffiths/ John McIntyre College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. The lead product candidate is TroVax®, a therapeutic vaccine for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. TroVax is in Phase III development. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NRAEAXFKEDPPFFE